A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year-1 interim analysis (P1-1.Virtual)Giancarlo Comi, Catherine Lubetzki, Douglas L. Arnold et al.|Neurology|2022Cited by 5
A multicenter, open label, single-arm, phase 3b study (CONSONANCE) to assess efficacy of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 1 interim analysis of cognition outcomes (P1-1.Virtual)Ralph Benedict, Helmut Butzkeuven, Maria Pia Sormani et al.|Neurology|2022Cited by 4